NeoGenomics (NasdaqCM:NEO) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsAbhishek Jain - EVP of Finance and Incoming CFOJeff Sherman - CFOKendra Webster - VP of Investor RelationsTony Zook - CEOWarren Stone - Chief Commercial OfficerConference Call ParticipantsAndrew Brackman - Equity Research AnalystAndrew Cooper - Equity Research AnalystBill Bonello - Equity Research AnalystDan Brennan - Equity Research AnalystDavid Westenberg - Equity Research AnalystMark Massaro - Equity Resear ...

Hillman Solutions (NasdaqGM:HLMN) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsJon Michael Adinolfi - COOMichael Koehler - VP of Investor Relations and TreasurerRocky Kraft - CFOConference Call ParticipantsAndrew Carter - AnalystBrian McNamara - AnalystDavid Manthey - AnalystLee Jagoda - AnalystStephen Volkmann - AnalystOperatorGood morning, and welcome to the fourth quarter and full year 2025 results and 2026 guidance presentation for Hillman Solutions Corp. My name is Liz, and I ...

eToro Group (NasdaqGS:ETOR) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsBrett Knoblauch - Head of Digital Asset ResearchBrian Bedell - DirectorCraig Siegenthaler - Managing DirectorDaniel Amir - Head of Investor RelationsDevin Ryan - Director of Financial Technology ResearchJames Yaro - Managing Director of Equity ResearchJohn Todaro - Managing DirectorMeron Shani - CFORobin Holby - Equity Research AssociateYoni Assia - CEOConference Call ParticipantsAlex Kramm - Equity Research ...

Financial Data and Key Metrics Changes - The company reported product revenue of $2.9 million in Q1 fiscal 2026, down from $3.3 million in Q1 fiscal 2025, but up 5.5% from $2.7 million in Q4 fiscal 2025 [11][12] - The net loss for Q1 fiscal 2026 was $1.4 million, or a loss of $0.03 per share, compared to a net income of $1.8 million, or $0.06 per share, in the same quarter of the prior year [13] - Cash and cash equivalents as of December 31, 2025, were $3.6 million, down from $6.6 million as of September 30, 2025 [13][14] Business Line Data and Key Metrics Changes - The OneRF brain ablation system saw nearly half of all ablations performed since its launch in Q1 fiscal 2026, indicating strong market penetration [4] - The OneRF trigeminal nerve ablation system initiated a limited commercial launch, treating nine patients across three centers, all reporting pain relief [5][6] Market Data and Key Metrics Changes - The company is working towards receiving ISO 13485 certification to facilitate international commercialization of its technology [5] - The company attended the American Epilepsy Society meeting, showcasing its technology and receiving positive feedback from medical professionals [4] Company Strategy and Development Direction - The company is projecting fiscal year 2026 sales to be at least $10.5 million, representing a minimum 17% increase from fiscal year 2025 [3] - The company is in discussions with strategic partners for potential licensing of its trigeminal nerve ablation technology and is prepared to commercialize independently if necessary [7][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued positive momentum from fiscal year 2025 and the progress across various programs [3][16] - The company is focused on accelerating its drug delivery program, expecting devices for commercial use in investigational studies by Q3 fiscal 2026, six months ahead of schedule [7][8] Other Important Information - The company appointed Jason Mills to its board of directors, bringing valuable experience from his previous roles in strategy and investment banking [10] - The company had no debt outstanding as of December 30, 2025, indicating a strong financial position [14][15] Q&A Session Summary Question: Update on trigeminal nerve ablation cases and interest from Zimmer - The nine cases were performed at three centers, with all patients reporting pain relief. Discussions with strategic partners are ongoing, but the company is ready to commercialize independently if needed [21][22] Question: Expectations for operating expenses for the rest of the year - SG&A expenses are expected to remain flat, while R&D expenses may fluctuate based on project phases [25] Question: Clinical feedback from neurologists or surgical teams - Feedback indicates success in reducing or eliminating seizures, with procedures being performed at patients' bedsides, enhancing ease of use [33][35] Question: Sales and marketing responsibilities with Zimmer - Zimmer is responsible for all marketing and sales costs, while the company provides training and field support [37] Question: Revenue breakdown for Q1 - Most revenue was from restocking, following the initial stocking order in the previous fiscal year [38]

CEVA (NasdaqGS:CEVA) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsAlek Valero - Equity Research AssociateAmir Panush - CEORichard Kingston - VP of Investor RelationsRuben Roy - Managing DirectorYaniv Arieli - CFOConference Call ParticipantsKevin Cassidy - Senior Research AnalystSuji Desilva - Managing Director and Senior Research AnalystOperatorPlease note this event is being recorded. I would now like to turn the conference over to Richard Kingston, Vice President of Market Intel ...

Herc (NYSE:HRI) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsAaron Birnbaum - PresidentLarry Silber - CEOLeslie Hunziker - SVP of Investor Relations and CommunicationsMark Humphrey - SVP and CFONeil Tyler - DirectorRob Wertheimer - Founding Partner of Machinery and New Mobility ResearchTami Zakaria - Executive DirectorConference Call ParticipantsKen Newman - VP and Equity Research AnalystKyle Menghas - VP and Equity Research AnalystMig Dobre - Associate Director of Research and Se ...

Armada Hoffler Properties (NYSE:AHH) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsAndrew Berger - Equity Research AssociateChelsea Forrest - VP of Investor RelationsCraig Ramiro - EVP of Asset ManagementJon Petersen - Managing DirectorMatthew Barnes-Smith - CFOShawn Tibbetts - Chairman, President, and CEOViktor Fediv - Senior Equity Research AssociateOperatorThis call is being recorded on Tuesday, February 17, 2026. I would now like to turn the conference over to Chelsea Forrest, ...

Fluor (NYSE:FLR) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsJamie Cook - Managing DirectorJason Landkamer - VP of Investor RelationsJim Breuer - CEOJohn Regan - CFONatalia Alvarez Iragorri - SVPSteven Fisher - Managing DirectorConference Call ParticipantsAndrew Wittman - Senior Research AnalystMichael Dudas - Equity Research AnalystSangita Jain - Director and Equity Research AnalystOperatorGood morning, and welcome to Fluor's fourth quarter and Full Year 2025 Earnings Conference ...

eToro Group (NasdaqGS:ETOR) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsBrett Knoblauch - Head of Digital Asset ResearchBrian Bedell - DirectorCraig Siegenthaler - Managing DirectorDaniel Amir - Head of Investor RelationsDevin Ryan - Director of Financial Technology ResearchJames Yaro - VP of Equity ResearchJohn Todaro - Managing DirectorMeron Shani - CFORobin Holby - Equity Research AssociateYoni Assia - CEOConference Call ParticipantsAlex Kramm - Equity Research AnalystDan Dole ...

Orion S.A. (NYSE:OEC) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsChris Kapsch - VP of Investor RelationsCorning Painter - CEOJohn Roberts - Managing DirectorJon Puckett - CFOJon Tanwanteng - Managing DirectorConference Call ParticipantsDan Rizzo - SVP and Equity AnalystJeff Zekauskas - Managing Director and Senior Equity Research AnalystJosh Spector - Equity Research AnalystOperatorGreetings. Welcome to the Orion S.A. fourth quarter 2025 earnings conference call. At this time, a ...